Faron Pharmaceuticals: Top-line Dose Variation Data From MATINS - Redeye

Faron has announced top-line data on dose variation from the phase I/II MATINS study with lead candidate Bexmarilimab. Redeye is encouraged by the results and looks forward to the further clinical development of the candidate.

Länk till analysen i sin helhet: https://www.redeye.se/research/855943/faron-pharmaceuticals-top-line-dose-variation-data-from-matins?utm_source=finwire&utm_medium=RSS